Cancer cocktails : ABL 001 – hitting one target twice Cancer cocktails : ABL 001 – hitting one target twice

  • Published 2017

Abstract

Medicines [2] ABL001 is a small molecule designed to inhibit BCR-ABL, the same protein hit by imatinib and nilotinib, which are used to treat chronic myelogenous leukemia. But ABL001 has a different mechanism of action. It doesn’t bind the active site of its target. Instead it binds a different region of BCR-ABL, forcing a conformational change that… (More)

Topics

  • Presentations referencing similar topics